Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1294-1297

  Zon, Robin T ^a   Nichols, Craig ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GERM CELL TUMOR; GONADOTROPIN BLOOD LEVEL; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031901265     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1294     Document Type: Article

References (22)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
2. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
3. Bosl G, Geller N, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
4. Droz JP, Kramer A, Rey A: Prognostic factors in metastatic disease. Semin Oncol 19:181-189, 1992
5. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
6. Einhorn LH, Donahue J: Cis-diaminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
7. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
8. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
9. 16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors: An Intergroup trial. Proc Am Soc Clin Oncol 14:239, 1995 (abstr)
10. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
11. Einhorn LH: Karnofsky Memorial Lecture. Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
12. Bajorin D, Sarosdy M, Pfister D, et al: A randomized trial of etoposide + cisplatin vs. Etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
13. Bokemeyer C, Schmoll HJ, Harstrick A, et al: A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumors. Eur J Cancer 29A:2225-2231, 1993
14. Daugaard G, Rorth M: Treatment of poor-risk germ-cell tumors with high-dose cisplatin and etoposide combined with bleomycin. Ann Oncol 3:277-282, 1992
15. Horwich A, Brada M, Nicholls J, et al: Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumors. Eur J Cancer Clin Oncol 25:177-184, 1989
16. Horwich A, Dearnaley DP, Norman A, et al: Accelerated chemotherapy for poor prognosis germ cell tumors. Eur J Cancer 30A:1607-1611, 1994
17. Bosl GJ, Geller NL, Vogelzang NJ, et al: Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5:436-440, 1987
18. Kaye S, Mead G, Fossa S, et al: An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing BEP to BOP-VIP. Proc Am Soc Clin Oncol 14:246, 1995 (abstr)
19. Motzer RJ, Cooper K, Geller NL, et al: Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer 65:2465-2470, 1990
20. Bosl GJ, Head MD: Serum tumor marker half-life during chemotherapy in patients with germ cell tumors. Int J Biol Markers 9:25-28, 1994
21. Stevens MJ, Norman AR, Dearnaley DP, et al: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13:87-92, 1995
22. Motzer R, Cooper K, Geller N, et al: The role of cisplatin and ifosfamide based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66: 2476-2481, 1992